人附睾蛋白4在上皮性卵巢癌中的应用价值

Application value of human epididymis protein 4 in epithelial ovarian cancer

近年来卵巢恶性肿瘤的发病率逐年升高并趋于年轻化。上皮性卵巢癌因早期常无明显症状,亦无有效监测手段,故多于晚期发现,预后较差。即使通过规范的手术及化疗,晚期上皮性卵巢癌的5年生存率为20%~30%,而早期上皮性卵巢癌(I~II期)患者5年生存率可达90%。上皮性卵巢癌患者的生存率与其分期及治疗效果相关。临床上一直在探索一种有效的监测手段,以期早期诊断并准确评估晚期上皮性卵巢癌的治疗效果,从而提高患者的生存率。人附睾蛋白4(human epididymis protein 4,HE4)作为近年来新发现的肿瘤标志物,在正常组织中呈限制性表达,在良性肿瘤组织中表达水平较低,在上皮性卵巢癌组织及血清中呈高水平表达。多项研究表明,HE4在早期上皮性卵巢癌的诊断、卵巢癌治疗效果及预后中有一定的应用价值。

In recent years,the incidence of ovarian malignant tumor is increasing year by year and the patients tend to be younger.Typically,epithelial ovarian cancer often has no obvious symptoms and no effective monitoring means in the early stage,and is usually diagnosed in the late stage with poor prognosis.Even with standard surgery and chemotherapy,the 5-year survival rate of advanced epithelial ovarian cancer is 20%–30%,while the 5-year survival rate of early epithelial ovarian cancer(I–II)patients is 90%.The survival rate of epithelial ovarian cancer is related with its stage and treatment effect.Clinically,an effective monitoring method has been explored for early diagnose and accurate evaluation of the treatment effect of advanced epithelial ovarian cancer,so as to improve the survival rate of patients.As a new tumor marker in recent years,human epididymis protein 4(HE4)has a limited expression in normal tissues,a low expression level in benign tumors,and a high expression level in epithelial ovarian cancer tissues and serum.Many studies have shown that HE4 has a certain value in the diagnosis,treatment,and prognosis of early epithelial ovarian cancer.